Systematic Review
Accepted on 07 Apr 2025
Cost-effectiveness analysis of Amivantamab plus Lazertinib, Lazertinib versus Osimertinib in NSCLC with EGFR
in Drugs Outcomes Research and Policies
- 109 views
Systematic Review
Accepted on 07 Apr 2025
in Drugs Outcomes Research and Policies
Review
Accepted on 07 Apr 2025
in Cardiovascular and Smooth Muscle Pharmacology
Original Research
Accepted on 07 Apr 2025
in Inflammation Pharmacology
Editorial
Accepted on 07 Apr 2025
in Ethnopharmacology
Review
Accepted on 07 Apr 2025
in Cardiovascular and Smooth Muscle Pharmacology
Original Research
Accepted on 07 Apr 2025
in Experimental Pharmacology and Drug Discovery
Review
Accepted on 07 Apr 2025
in Renal Pharmacology
Systematic Review
Accepted on 07 Apr 2025
in Pharmacoepidemiology
Original Research
Accepted on 07 Apr 2025
in Experimental Pharmacology and Drug Discovery
Review
Accepted on 07 Apr 2025
in Pharmacology of Infectious Diseases
Original Research
Accepted on 07 Apr 2025
in Pharmacology of Anti-Cancer Drugs
Original Research
Accepted on 07 Apr 2025
in Gastrointestinal and Hepatic Pharmacology
Original Research
Accepted on 07 Apr 2025
in Gastrointestinal and Hepatic Pharmacology
Systematic Review
Accepted on 07 Apr 2025
in Gastrointestinal and Hepatic Pharmacology
Mini Review
Accepted on 07 Apr 2025
in Pharmacology of Anti-Cancer Drugs
Original Research
Accepted on 07 Apr 2025
in Cardiovascular and Smooth Muscle Pharmacology